Filtered By:
Infectious Disease: SARS
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 388 results found since Jan 2013.
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.ABSTRACTThe world is presently in crisis facing an outbreak of a health-threatening microorganism known as COVID-19, responsible for causing uncommon viral pneumonia in humans. The virus was first reported in Wuhan, China, in early December 2019, and it quickly became a global concern due to the pandemic. Challenges in this regard have been compounded by the emergence of several variants such as B.1.1.7, B.1.351, P1, and B.1.617, which show an increase in transmission power and resistance to therapies and vaccines. Ongoing researches are ...
Source: Biomed Res - September 7, 2023 Category: Research Authors: Narjess Bostanghadiri Pardis Ziaeefar Morvarid Golrokh Mofrad Parsa Yousefzadeh Ali Hashemi Davood Darban-Sarokhalil Source Type: research
Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults - United States, December 2020-March 2023
This report includes analysis of data on self-reported symptoms collected from 1,296 adults with COVID-like illness who were tested for SARS-CoV-2 using a Food and Drug Administration-approved polymerase chain reaction or antigen test at the time of enrollment and reported symptoms at 3-month intervals for 12 months. Prevalence of any symptom decreased substantially between baseline and the 3-month follow-up, from 98.4% to 48.2% for persons who received a positive SARS-CoV-2 test results (COVID test-positive participants) and from 88.2% to 36.6% for persons who received negative SARS-CoV-2 test results (COVID test-negative...
Source: MMWR Morb Mortal Wkl... - August 10, 2023 Category: Epidemiology Authors: Juan Carlos C Montoy James Ford Huihui Yu Michael Gottlieb Dana Morse Michelle Santangelo Kelli N O'Laughlin Kevin Schaeffer Pamela Logan Kristin Rising Mandy J Hill Lauren E Wisk Wafah Salah Ahamed H Idris Ryan M Huebinger Erica S Spatz Robert M Rodrigue Source Type: research
Structural-Based Virtual Screening of FDA-Approved Drugs Repository for NSP16 Inhibitors, Essential for SARS-COV-2 Invasion Into Host Cells: Elucidation From MM/PBSA Calculation
Bioinform Biol Insights. 2023 Jul 31;17:11779322231171777. doi: 10.1177/11779322231171777. eCollection 2023.ABSTRACTNSP16 is one of the structural proteins of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) necessary for its entrance to the host cells. It exhibits 2'O-methyl-transferase (2'O-MTase) activity of NSP16 using methyl group from S-adenosyl methionine (SAM) by methylating the 5-end of virally encoded mRNAs and shields viral RNA, and also controls its replication as well as infection. In the present study, we used in silico approaches of drug repurposing to target and inhibit the SAM binding site ...
Source: Bioinformatics and Biology Insights - August 3, 2023 Category: Bioinformatics Authors: Subodh Kumar Harvinder Singh Manisha Prajapat Phulen Sarma Anusuya Bhattacharyya Hardeep Kaur Gurjeet Kaur Nishant Shekhar Karanveer Kaushal Kalpna Kumari Seema Bansal Saniya Mahendiratta Arushi Chauhan Ashutosh Singh Rahul Soloman Singh Saurabh Sharma Pr Source Type: research
